Noninvasive electroporation could forestall burn scars: Study

While burn scars are not life-threatening, they can lead to lifelong physical, psychological and social difficulties. A team from Tel Aviv University and Harvard University have used pulsed electric fields to stop the formation of scar tissue in rats.

"People don't die from scars, but they do suffer from them," said Dr. Alexander Golberg of Tel Aviv University, in a statement. "We believe that the technology we developed, called partial irreversible electroporation (pIRE), can be used to prevent debilitating burn scars from forming."

The noninvasive method partially destroys cells in a burn wound using microsecond-pulsed, high-voltage, nonthermal electric fields, according to a statement. This causes irreversible damage to collagen cells, the proliferation of which causes permanent scarring at a burn injury site.


Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

The researchers administered the treatment to rats with burn injuries in 5 sessions over the course of 6 months. They found a 58% reduction in scar area in the treated rats compared to untreated scars. While the results are promising, the scientists had to take care not to create a new wound or to counteract scarring too much, which can impede the body’s natural healing.

Other methods used to treat scarring include surgery, laser therapy and electron beam irradiation, Dr. Golberg said. But these have resulted only in “modest improvements.”

"Scarring is a very complex process, involving inflammation and metabolism," said Dr. Golberg. "We have found a way to partially prevent scar formation in animal models. Next we need to raise funding to develop a device for the clinical study on humans."

- read the statement
- here's the abstract

Related Articles:
Avita nabs $54M BARDA contract for ongoing pivotal trial, stockpile of burn injury device
Microneedle patch reduces scar tissue in Singapore studies

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.